和鉑醫藥(02142.HK):抗CTLA-4抗體HBM4003一期研究獲積極結果
和鉑醫藥(02142.HK)公佈,集團在澳洲進行的實體瘤HBM4003之I期劑量爬坡臨牀試驗取得積極結果。臨牀數據摘要已於2021年歐洲腫瘤內科學會(ESMO)年會上以電子海報形式發佈。於I期研究獲取的數據乃新一代抗CTLA-4全人源單克隆僅重鏈抗體(HCAb)應用於實體瘤的首例臨牀實證,數據顯示HBM4003療效令人鼓舞,並具有良好的安全特性。
集團指,於I期研究中的所有療法不良相關事件(TRAEs)均爲可控和可逆。HBM4003單一療法的初始抗腫瘤功效令人鼓舞,尤其是兩名經歷多線治療的受試者對HBM4003單藥治療產生了應答,其中一名晚期肝癌患者之前還接受了PD-1治療。
HBM4003是抗CTLA-4全人源單克隆僅重鏈抗體(HCAb),產生自Harbour Mice平臺。通過顯着增強的ADCC(抗體依賴的細胞毒性作用)活性,HBM4003對腫瘤組織中高表達CTLA-4的Treg細胞具有極高的特異性剔除。其強力的抗腫瘤療效、差異化的藥代動力學特徵和持久的藥效展現出良好的產品特性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.